Ataxin-3 (ATXN3) is a ubiquitously expressed deubiquitinating enzyme (DUB) belonging to the Josephin family of cysteine proteases that catalyzes the removal of ubiquitin chains from target proteins. The protein contains a catalytic Josephin domain at its N-terminus, followed by a variable number of ubiquitin-interacting motifs (UIMs) that facilitate substrate recognition and binding. Mutations in the ATXN3 gene, specifically expansions of a polyglutamine (polyQ) repeat, cause Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph disease (MJD), one of the most common inherited ataxias worldwide[^1].
Structure and Molecular Architecture
Ataxin-3 is a 361-amino acid protein in its wild-type form, characterized by a highly organized domain structure critical for its biological function:
Ataxin-3 (ATXN3) is a ubiquitously expressed deubiquitinating enzyme (DUB) belonging to the Josephin family of cysteine proteases that catalyzes the removal of ubiquitin chains from target proteins. The protein contains a catalytic Josephin domain at its N-terminus, followed by a variable number of ubiquitin-interacting motifs (UIMs) that facilitate substrate recognition and binding. Mutations in the ATXN3 gene, specifically expansions of a polyglutamine (polyQ) repeat, cause Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph disease (MJD), one of the most common inherited ataxias worldwide[^1].
Structure and Molecular Architecture
Ataxin-3 is a 361-amino acid protein in its wild-type form, characterized by a highly organized domain structure critical for its biological function:
Josephin Domain (JosD): The N-terminal catalytic domain (amino acids 1-180) containing the characteristic papain-fold protease fold with the active site composed of catalytic residues Cys67, His117, and Asp127. This domain is responsible for the deubiquitinating enzymatic activity and shares structural homology with other USP-family deubiquitinases.
Ubiquitin-Interacting Motifs (UIMs): Located in the C-terminal region, these 20-amino acid motifs recognize and bind polyubiquitin chains with high specificity. Wild-type ataxin-3 typically contains three UIMs, though the exact number can vary between species and individuals due to the polymorphic nature of their encoding sequences.
Flexible Interdomain Region: A loosely structured linker region connecting the catalytic domain to the UIM region allows conformational flexibility, enabling the enzyme to access diverse substrate configurations and ubiquitin chain topologies.
Polyglutamine Tract: In disease-associated variants, an expanded polyQ repeat (typically 55-89 glutamine residues, compared to 10-44 in normal individuals) is inserted in the C-terminal region immediately after the UIMs. This expansion dramatically alters protein conformation, localization, and aggregation propensity.
Biochemical Functions and Mechanisms
Deubiquitination and Substrate Specificity
Ataxin-3 functions as a highly selective deubiquitinating enzyme with preference for K63-linked and K11-linked polyubiquitin chains, though it can also process other chain linkages with lower efficiency. The enzyme exhibits both exo- and endopeptidase activity, capable of removing entire ubiquitin chains or cleaving individual ubiquitin molecules from modified substrates. Key functional aspects include:[^2]
Chain-linkage selectivity: The substrate-binding pocket and UIM-mediated recognition confer specificity for particular ubiquitin topologies, allowing ataxin-3 to distinguish between different cellular signaling pathways regulated through ubiquitination[^3].
Regulation of ER-associated degradation (ERAD): Ataxin-3 participates in the processing of polyubiquitinated misfolded proteins destined for proteasomal degradation, particularly through interactions with E2 enzymes (UbcH5 and UbcH7) and the E3 ligase parkin in quality control pathways.
DNA damage response and genomic stability: The protein localizes to sites of DNA damage where it cooperates with RAD23 and other DNA repair factors to regulate ubiquitin chain topology at damage foci, influencing the recruitment and activation of repair machinery[^4].
Modulation of stress response pathways: Ataxin-3 regulates NF-κB signaling through deubiquitination of IκB kinase (IKK), controlling inflammatory responses and apoptotic threshold in neurons under cellular stress conditions[^5].
Protein-protein interactions: The enzyme interacts with numerous binding partners including ubiquilin proteins, E2 conjugating enzymes, and stress-response chaperones like Hsp40 and Hsp70, positioning it as a critical node in the proteostasis network.
Molecular Pathology in Spinocerebellar Ataxia Type 3
Polyglutamine Expansion and Protein Misfolding
The pathogenic mechanism of SCA3 involves a toxic gain-of-function mechanism triggered by polyglutamine tract expansion. When the polyQ repeat exceeds approximately 50 residues, ataxin-3 undergoes a dramatic conformational change that promotes:[^6]
Abnormal protein aggregation: The expanded polyQ tract nucleates the formation of β-sheet-rich aggregates that progressively accumulate in the cytoplasm and nucleus of affected neurons. These aggregates initially form as diffuse inclusions but subsequently coalesce into large intranuclear inclusions (INIs) characteristic of SCA3 pathology. The aggregation kinetics appear to be length-dependent, with longer repeats (>70 glutamines) showing accelerated aggregation rates and earlier disease onset.
Loss and gain-of-function toxicity: While polyQ expansion impairs the normal deubiquitinating activity of ataxin-3, the primary pathogenic mechanism involves toxic aggregate accumulation rather than simple loss of enzymatic function. The accumulating aggregates sequester wild-type ataxin-3, other deubiquitinating enzymes, and critical proteostasis factors including ubiquilin-1, parkin, and molecular chaperones, creating a "protein aggregation sink" that progressively impairs cellular quality control systems.
Sequestration of proteostasis machinery: Mutant ataxin-3 aggregates recruit and sequester essential components of the ubiquitin-proteasome system (UPS) and autophagy pathways, leading to secondary accumulation of ubiquitinated protein aggregates and collapse of proteostatic balance in vulnerable neuronal populations[^7].
Neuronal Vulnerability and Selective Vulnerability
SCA3 exhibits striking selective vulnerability, with preferential degeneration of specific neuronal populations despite ubiquitous ataxin-3 expression:[^8]
Cerebellar pathology: Purkinje cells and dentate nucleus neurons show the most severe pathology, with progressive loss of these populations correlating with the characteristic ataxic motor symptoms. The basis for cerebellar selectivity remains partially unclear but likely involves higher basal metabolic demands, limited regenerative capacity, and particular susceptibility to proteostatic stress.
Brainstem involvement: Substantia nigra dopaminergic neurons, oculomotor nuclei, and vestibular nuclei show progressive degeneration, contributing to parkinsonism, ophthalmoplegia, and postural instability in advanced disease stages.
Spinal cord pathology: Motor neurons and spinocerebellar tract neurons undergo selective degeneration, particularly in patients with longer polyQ repeats and earlier disease onset, suggesting a threshold effect for toxicity based on repeat length.
The molecular basis for selective vulnerability likely involves differential expression of ataxin-3 interacting proteins, regional variations in proteostatic capacity, differences in neuronal activity patterns, and possibly region-specific alternative splicing of ataxin-3 that alters its aggregation propensity or subcellular localization.
Mechanism of Neuronal Cell Death
Pathogenic ataxin-3 aggregates trigger multiple cell death pathways:
Mitochondrial dysfunction: Ataxin-3 aggregates impair mitochondrial dynamics and function, leading to reduced ATP production and increased reactive oxygen species (ROS) generation. The protein localizes to mitochondria through interaction with TOM70, and polyQ-expanded ataxin-3 disrupts this relationship, compromising mitochondrial quality control.
Excitotoxicity and calcium dysregulation: Altered calcium handling and excessive glutamate receptor signaling contribute to neuronal death, potentially through impaired deubiquitination of calcium-handling proteins and enhanced excitatory neurotransmission in cerebellar circuits.
Transcriptional dysregulation: Sequestration of transcription factors and coactivators by ataxin-3 aggregates leads to selective alterations in gene expression patterns, including downregulation of neuroprotective genes and upregulation of pro-apoptotic pathways.
Caspase activation and apoptosis: Multiple converging pathways lead to activation of caspase-3 and caspase-9, with some evidence suggesting that mutant ataxin-3 itself may be cleaved by caspases, generating truncate
References
[^1]: Unknown et al. Extracellular vesicles-associated AAVs for the treatment of Machado-Joseph disease.. Molecular therapy : the journal of the American Society of Gene Therapy. 2026. PMID:41077785. [^2]: Unknown et al. Autophagy- and oxidative stress-related protein deregulation mediated by extracellular vesicles of human MJD/SCA3 iPS.... Cell death & disease. 2025. PMID:40374597. [^3]: Unknown et al. TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves.... Scientific reports. 2024. PMID:39242684. [^4]: Unknown et al. Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2024. PMID:38258931. [^5]: Unknown et al. Small Molecules Inducing Autophagic Degradation of Expanded Polyglutamine Protein through Interaction with Both Mutan.... International journal of molecular sciences. 2024. PMID:39409036. [^6]: R et al. Human CSF proteogenomics links genetic variation to neurodegenerative disease proteins.. medRxiv : the preprint server for health sciences. 2026. PMID:41757182. [^7]: Unknown et al. Valosin-Containing Protein as a therapeutic target in CAG repeat-driven Spinocerebellar ataxias: Integrative transcri.... Computational biology and chemistry. 2026. PMID:41435767. [^8]: Unknown et al. Diffusion along perivascular spaces as a marker for Glymphatic system impairment in spinocerebellar Ataxia type 3.. Neurobiology of disease. 2026. PMID:41443376.